News & Updates

Show Multimedia Only
Nirmatrelvir-ritonavir benefits persist against COVID

Nirmatrelvir-ritonavir benefits persist against COVID

07 Nov 2023 byElvira Manzano

Management of most adults with COVID-19, particularly those with mild-to-moderate disease, is increasingly occurring in the outpatient setting due to the availability of effective treatment options. 

07 Nov 2023
Histologic inflammation of IBD a risk factor for serious infections Histologic inflammation of IBD a risk factor for serious infections

Histologic inflammation of IBD a risk factor for serious infections

03 Nov 2023

Among individuals with inflammatory bowel disease (IBD), histologic inflammation appears to contribute to an increased risk of serious infections such as sepsis, according to a study, suggesting that achieving remission may reduce infections in IBD.

03 Nov 2023